{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:46:23Z","timestamp":1790703983486,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Effects of disease progression on healthcare resource utilization (HRU) and costs among multiple myeloma (MM) patients with \u22651 line of therapy (LOT) who received their first stem cell transplant (SCT) within 1 year of initial MM diagnosis were estimated using a large US claims database. Disease progression was defined as advancement to the next LOT, bone metastasis, hypercalcemia, soft tissue plasmacytoma, skeletal related events, acute kidney disease, or death within 12 months of LOT initiation. Annual HRU and costs in the first three LOTs (L1\u2013L3) were compared for patients with versus without disease progression using inverse probability of treatment weighting to adjust for differences between groups in baseline characteristics. In all LOTs, mean annual hospitalizations and healthcare costs were greater for patients with versus without progression. Total incremental annual costs among patients with versus without progression in L1\u2013L3 were $18,359, $87,055, and $71,917, respectively, among LOTs initiated between 2006 and 2018. In LOTs initiated between 2013 and 2018, the figures were $46,024, $100,329, and $101,942 in L1\u2013L3, respectively. The economic burden of disease progression is substantial in this population of MM patients who underwent SCT and received systemic anti-myeloma therapy.<\/jats:p>","DOI":"10.1038\/s41408-021-00431-5","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T14:03:08Z","timestamp":1620050588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5796-2580","authenticated-orcid":false,"given":"May","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Delea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"431_CR1","unstructured":"American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2020. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2020\/cancer-facts-and-figures-2020.pdf. Accessed 24 Feb 2020."},{"key":"431_CR2","unstructured":"National Comprehensive Cancer Network. The NCCN Guidelines\u00ae Version 2. 2020 Multiple Myeloma. https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf Accessed 24 Feb 2020."},{"key":"431_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"431_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","volume":"21","author":"K Podar","year":"2020","unstructured":"Podar, K., Shah, J., Chari, A., Richardson, P. G. & Jagannath, S. Selinexor for the treatment of multiple myeloma. Exp. Opin. Pharmacother. 21, 399\u2013408 (2020).","journal-title":"Exp. Opin. Pharmacother."},{"key":"431_CR5","doi-asserted-by":"publisher","unstructured":"McMillan A., Warcel D., Popat R. Antibody-drug conjugates for multiple myeloma [published online ahead of print, 2020 Aug 12]. Exp. Opin. Biol. Ther. 2020;1\u201313. https:\/\/doi.org\/10.1080\/14712598.2020.1802422.","DOI":"10.1080\/14712598.2020.1802422"},{"key":"431_CR6","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1200\/JCO.2016.34.15_suppl.8060","volume":"34","author":"M Hagiwara","year":"2016","unstructured":"Hagiwara, M., Panjabi, S., Sharma, A., Chen, Y. J. & Delea, T. E. Retrospective study of frequency and cost of multiple myeloma (MM) complications and treatment (Tx) related adverse events (AEs). J. Clin. Oncol. 34, 8060\u20138060 (2016).","journal-title":"J. Clin. Oncol."},{"key":"431_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","volume":"18","author":"A Teitelbaum","year":"2013","unstructured":"Teitelbaum, A., Ba-Mancini, A., Huang, H. & Henk, H. J. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 18, 37\u201345 (2013).","journal-title":"Oncologist."},{"key":"431_CR8","unstructured":"Arikian S. R. et al. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr. Med. Res. Opin. 17:1\u201311 (2015)."},{"key":"431_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/10428194.2017.1361035","volume":"59","author":"JP MacEwan","year":"2018","unstructured":"MacEwan, J. P. et al. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. Leukemia Lymphoma 59, 941\u2013949 (2018).","journal-title":"Leukemia Lymphoma"},{"key":"431_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e20040","volume":"36","author":"S Pandya","year":"2018","unstructured":"Pandya, S. et al. Economic burden of early progression in newly-diagnosed multiple myeloma patients. J. Clin. Oncol. 36, e20040 (2018).","journal-title":"J. Clin. Oncol."},{"key":"431_CR11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1200\/JCO.2018.36.30_suppl.194","volume":"36","author":"Z Clancy","year":"2018","unstructured":"Clancy, Z. et al. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts). J. Clin. Oncol. 36, 194 (2018).","journal-title":"J. Clin. Oncol."},{"key":"431_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1080\/13696998.2018.1457531","volume":"21","author":"D Bhowmik","year":"2018","unstructured":"Bhowmik, D., Hines, D. M., Intorcia, M. & Wade, R. L. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. J. Med. Econ. 21, 622\u2013628 (2018).","journal-title":"J. Med. Econ."},{"key":"431_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/10428194.2019.1648802","volume":"61","author":"M Hagiwara","year":"2020","unstructured":"Hagiwara, M., Panjabi, S., Delea, T. E., Yucel, E. & Fonseca, R. Burden of disease progression in patients with multiple myeloma in the US. Leukemia Lymphoma 61, 47\u201355 (2020).","journal-title":"Leukemia Lymphoma"},{"key":"431_CR14","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin, P. C. & Stuart, E. A. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat. Med. 34, 3661\u20133679 (2015).","journal-title":"Stat. Med."},{"key":"431_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.3334","volume":"22","author":"ES Johnson","year":"2013","unstructured":"Johnson, E. S. et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol. Drug Saf. 22, 1\u20136 (2013).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"431_CR16","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1182\/blood.V122.21.3202.3202","volume":"122","author":"M Klever","year":"2013","unstructured":"Klever, M. et al. Vorinostat (V) in combination with bortezomib (B), doxorubicin (D) and dexamethasone (D) (VBDD) in patients with refractory or relapsed multiple myeloma: an intersim Phase I\/II analysis. Blood 122, 3202 (2013).","journal-title":"Blood"},{"key":"431_CR17","unstructured":"Truven Health Analytics, IBM Watson Health. The Truven Health MarketScan Databases for Health Services Researchers. https:\/\/truvenhealth.com\/portals\/0\/assets\/2017_MarketScan_Databases_Health_Services_Researchers.pdf. Accessed 23 Jan 2019."},{"key":"431_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2015.1105202","volume":"32","author":"X Song","year":"2016","unstructured":"Song, X., Cong, Z. & Wilson, K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr. Med. Res. Opin. 32, 1 (2016). 95-103.","journal-title":"Curr. Med. Res. Opin."},{"key":"431_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2307\/2533947","volume":"53","author":"DY Lin","year":"1997","unstructured":"Lin, D. Y., Feuer, E. J., Etzioni, R. & Wax, Y. Estimating medical costs from incomplete follow-up data. Biometrics. 53, 419\u2013434 (1997).","journal-title":"Biometrics."},{"key":"431_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/CLEP.S105613","volume":"9","author":"KE Mues","year":"2017","unstructured":"Mues, K. E. et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled population in the US. Clin. Epidemiol. 9, 267\u2013277 (2017).","journal-title":"Clin. Epidemiol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00431-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:40:32Z","timestamp":1669909232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00431-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00431-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"20 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.B. is currently an employee of Amgen, Inc. and S.P. and E.Y. were employees of Amgen, Inc. and all hold Amgen Stock. R.F. is a consultant for Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK, and AbbVie, and is on the Scientific Advisory Board of Adaptive Biotechnologies and OncoTracker. M.H. and T.E.D. received research funding from Amgen, Celgene, EMD Serono, Jazz, Merck, Novartis, Pfizer, Sanofi, Seattle Genetics, and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"35"}}